Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0524 to Improve Tolerability of Extended-Release Niacin After Drug Holiday
2006-003107-39Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of laropiprant in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoint: Maximum Global Flushing Severity Score (GFSS) during first 7 days post-drug holiday. Started Jul 2006; status: completed.
02
Drugs
laropiprant
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2006-003107-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003107-39.